Skip to main content
Sign In

Director's Corner

CCTSI Director Ronald J. Sokol, MD

CCTSI Director Ron Sokol, MD
Ron Sokol, MD
Winter 2017
As many of you know, we submitted our CTSA NIH 5-year grant renewal in May of this year. In late September we learned of our impact score and we were thrilled to learn it was 13! (Scores can range from 10 to 90 with 10 being best.) We won’t receive our official notice of grant award for several more months, but we are gratified that the review committee gave our renewal such a favorable score. As a result, we anticipate five years of funding to begin in late spring. Thanks to each and every one of you (and there were many) who played a role in our submission.

In order to keep our research community informed of changes that we anticipate in the CCTSI over the next five years, we have launched a series of Town Hall meetings. We held the first one on December 4 on the Anschutz Medical Campus. Future Town Hall meetings will take place at Children’s Hospital Colorado, National Jewish Health, University of Colorado Boulder and Colorado State University. Keep an eye out for emails promoting these upcoming events.

I wanted to take a moment to celebrate the accomplishments of a CCTSI colleague, Phil Zeitler, MD, who is the medical director of the pediatric Clinical Translational Research Center (CTRC). Dr. Zeitler has been appointed the Editor-in-Chief of Pediatric Diabetes, the leading journal devoted to disseminating new knowledge relating to the epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes in children, adolescents and young adults. Congratulations Phil!

Speaking of our CTRCs, last week our UCH and Children’s Colorado CTRC units hit a milestone that is worth noting: the University of Colorado AIDS Clinical Trials Unit celebrated 25 years of research, having participated in over 177 clinical trials with 2,500 participants, many conducted in our CTRC units. You can read more about the 25th anniversary of the clinical trials here​. Currently, 10 ACTG clinical trials are open and enrolling with five additional research studies in participant follow-up. In addition to the selfless study participants at our site, hundreds of thousands more people have participated in industry sponsored clinical trials and other HIV research studies around the world. As a testament to their dedication, some of those brave initial study participants continue to be actively involved in HIV research to this day. It was through their contributions to scientific research that led to the development of effective treatment options for all people diagnosed with HIV. As we celebrate our 25th year of being an active ACTG Network clinical research site, I want to extend kudos to Dr. Thomas Campbell who has been the Principal Investigator of the Colorado AIDS Clinical Trial Unit since 2004. We wish to thank every single one of our study participants for their commitment to furthering clinical research here in Colorado. Because of you, we are closer than ever to the beginning of the end of the HIV/AIDS pandemic.

Finally on behalf of the CCTSI we would like to extend our heartfelt condolences to the family of Dick Traystman, PhD who passed away last month. Dick, as Vice Chancellor of Research, was a staunch supporter of the CCTSI and all that we do for the campus, hospitals and communities. Dick will be deeply missed.
All the best,




Photo above: Constance Benson, MD, Robert “Chip” Schooley, MD, and Thomas Campbell, MD​

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.